This is a study in healthy participants designed to assess the effect of multiple doses of itraconazole, gemfibrozil, or carbamazepine on the drug levels of a single-dose of BMS-986278.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
47
Specified dose on specified days
Specified dose on specified days
Specified dose on specified days
Local Institution - 0001
Québec, CA, Canada
Maximum observed plasma concentration (Cmax)
Time frame: Up to 33 days
Area under the plasma concentration-time curve from time zero to time of the last quantifiable concentration (AUC[0-T])
Time frame: Up to 33 days
Area under the plasma concentration-time curve from time zero extrapolated to infinite time (AUC[INF])
Time frame: Up to 33 days
Number of participants with adverse events (AEs)
Time frame: Up to 33 days
Number of participants with physical examination abnormalities
Time frame: Up to 33 days
Number of participants with vital sign abnormalities
Time frame: Up to 33 days
Number of participants with electrocardiogram (ECG) abnormalities
Time frame: Up to 33 days
Number of participants with clinical laboratory abnormalities
Time frame: Up to 33 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Specified dose on specified days